News | September 28, 2021
Bal Pharma ramps up API capacity of Gliclazide
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
As competition intensifies in the obesity treatment market, a next-generation therapy may be in development.
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
The double-blind, dose-finding ZUPREME-1 trial enrolled 485 adults with overweight or obesity
CEO Stéphane Bancel framed the changes as essential to scaling the business
Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
Highlights India’s advances in pharmacopoeial science, regulatory standards, and global harmonization efforts at the 16th International Meeting of World Pharmacopoeias
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
